BR112015015131A2 - método, aparelho, mídia de armazenamento não transitório, programa de computador, e produto - Google Patents
método, aparelho, mídia de armazenamento não transitório, programa de computador, e produtoInfo
- Publication number
- BR112015015131A2 BR112015015131A2 BR112015015131A BR112015015131A BR112015015131A2 BR 112015015131 A2 BR112015015131 A2 BR 112015015131A2 BR 112015015131 A BR112015015131 A BR 112015015131A BR 112015015131 A BR112015015131 A BR 112015015131A BR 112015015131 A2 BR112015015131 A2 BR 112015015131A2
- Authority
- BR
- Brazil
- Prior art keywords
- transient storage
- computer program
- product
- storage media
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N5/00—Computing arrangements using knowledge-based models
- G06N5/04—Inference or reasoning models
- G06N5/048—Fuzzy inferencing
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Theoretical Computer Science (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Software Systems (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Evolutionary Computation (AREA)
- Data Mining & Analysis (AREA)
- Artificial Intelligence (AREA)
- Computing Systems (AREA)
- Automation & Control Theory (AREA)
- Mathematical Physics (AREA)
- General Physics & Mathematics (AREA)
- Fuzzy Systems (AREA)
- Computational Linguistics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
resumo método, aparelho, mídia de armazenamento não transitório, programa de computador, e produto o presente pedido refere-se principalmente a métodos específicos para inferir a atividade de uma via de sinalização celular em um tecido e/ou em células de um paciente médico com base em ao menos um nível de expressão de um ou mais genes alvo da via de sinalização celular medida em uma amostra extraída do tecido e/ou das células do paciente médico, um aparelho compreendendo um processador digital configurado para executar tais métodos e uma mídia de armazenamento não transitório que armazena instruções que são executáveis por um dispositivo de processamento digital para executar tais métodos. 1/1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261745839P | 2012-12-26 | 2012-12-26 | |
PCT/IB2013/061066 WO2014102668A2 (en) | 2012-12-26 | 2013-12-18 | Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions; |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015015131A2 true BR112015015131A2 (pt) | 2017-07-11 |
Family
ID=50156797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015015131A BR112015015131A2 (pt) | 2012-12-26 | 2013-12-18 | método, aparelho, mídia de armazenamento não transitório, programa de computador, e produto |
Country Status (13)
Country | Link |
---|---|
US (2) | US11306360B2 (pt) |
EP (1) | EP2938745B1 (pt) |
JP (2) | JP6449779B2 (pt) |
KR (1) | KR102279844B1 (pt) |
CN (2) | CN111961726A (pt) |
AU (2) | AU2013368945B2 (pt) |
BR (1) | BR112015015131A2 (pt) |
CA (1) | CA2896414C (pt) |
DK (1) | DK2938745T3 (pt) |
ES (1) | ES2878196T3 (pt) |
MX (1) | MX2015008177A (pt) |
RU (1) | RU2721130C2 (pt) |
WO (1) | WO2014102668A2 (pt) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI648273B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類(三) |
CA2909991A1 (en) | 2013-04-26 | 2014-10-30 | Koninklijke Philips N.V. | Medical prognosis and prediction of treatment response using multiple cellular signalling pathway activities |
EP3013986B1 (en) | 2014-01-03 | 2016-11-16 | Koninklijke Philips N.V. | Assessment of the pi3k cellular signaling pathway activity using mathematical modelling of target gene expression |
JP7065609B6 (ja) | 2014-10-24 | 2022-06-06 | コーニンクレッカ フィリップス エヌ ヴェ | 複数の細胞シグナル伝達経路活性を用いる治療応答の医学的予後及び予測 |
CN108064380A (zh) * | 2014-10-24 | 2018-05-22 | 皇家飞利浦有限公司 | 使用多种细胞信号传导途径活性的医学预后和治疗反应的预测 |
WO2016062891A1 (en) | 2014-10-24 | 2016-04-28 | Koninklijke Philips N.V. | ASSESSMENT OF TGF-β CELLULAR SIGNALING PATHWAY ACTIVITY USING MATHEMATICAL MODELLING OF TARGET GENE EXPRESSION |
EP3334837B1 (en) | 2015-08-14 | 2020-12-16 | Koninklijke Philips N.V. | Assessment of nfkb cellular signaling pathway activity using mathematical modelling of target gene expression |
US20190128899A1 (en) * | 2016-06-13 | 2019-05-02 | Koninklijke Philips N.V. | Method for inferring activity of a transcription factor of a signal transduction pathway in a subject |
KR102608922B1 (ko) * | 2016-11-17 | 2023-12-01 | 난트바이오 인코포레이티드 | 추론된 항암 경로의 검증 |
WO2018096076A1 (en) | 2016-11-25 | 2018-05-31 | Koninklijke Philips N.V. | Method to distinguish tumor suppressive foxo activity from oxidative stress |
EP3431582A1 (en) | 2017-07-18 | 2019-01-23 | Koninklijke Philips N.V. | Cell culturing materials |
EP3692170A1 (en) | 2017-10-02 | 2020-08-12 | Koninklijke Philips N.V. | Determining functional status of immune cells types and immune response |
EP3462349A1 (en) | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of notch cellular signaling pathway activity using mathematical modelling of target gene expression |
EP3461915A1 (en) * | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression |
EP3461916A1 (en) | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of jak-stat3 cellular signaling pathway activity using mathematical modelling of target gene expression |
EP3502279A1 (en) * | 2017-12-20 | 2019-06-26 | Koninklijke Philips N.V. | Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression |
CN108187050A (zh) * | 2018-01-18 | 2018-06-22 | 石河子大学 | 抑制食管癌细胞增殖的药物 |
WO2020037203A2 (en) * | 2018-08-17 | 2020-02-20 | Genentech, Inc. | Diagnostic and therapeutic methods for the treatment of breast cancer |
EP3812474A1 (en) | 2019-10-22 | 2021-04-28 | Koninklijke Philips N.V. | Methods of prognosis in high-grade serous ovarian cancer |
US11674185B2 (en) | 2019-05-03 | 2023-06-13 | Koninklijke Philips N.V. | Methods of prognosis in high-grade serous ovarian cancer |
EP3739588A1 (en) | 2019-05-13 | 2020-11-18 | Koninklijke Philips N.V. | Assessment of multiple signaling pathway activity score in airway epithelial cells to predict airway epithelial abnormality and airway cancer risk |
EP3822368A1 (en) | 2019-11-14 | 2021-05-19 | Koninklijke Philips N.V. | Assessment of pr cellular signaling pathway activity using mathematical modelling of target gene expression |
EP3835433A1 (en) | 2019-12-12 | 2021-06-16 | Koninklijke Philips N.V. | Notch signaling pathway activity as prognostic marker in bladder cancer |
CN111166884B (zh) * | 2020-01-15 | 2021-12-03 | 广州中医药大学第一附属医院 | Foxf1基因在制备用于骨质疏松症药物中的应用 |
EP3882363A1 (en) | 2020-03-17 | 2021-09-22 | Koninklijke Philips N.V. | Prognostic pathways for high risk sepsis patients |
EP3978628A1 (en) | 2020-10-01 | 2022-04-06 | Koninklijke Philips N.V. | Prognostic pathways for viral infections |
WO2021209567A1 (en) | 2020-04-16 | 2021-10-21 | Koninklijke Philips N.V. | Prognostic pathways for viral infections |
EP3940704A1 (en) | 2020-07-14 | 2022-01-19 | Koninklijke Philips N.V. | Method for determining the differentiation state of a stem cell |
EP3960875A1 (en) | 2020-08-28 | 2022-03-02 | Koninklijke Philips N.V. | Pcr method and kit for determining pathway activity |
EP3965119A1 (en) | 2020-09-04 | 2022-03-09 | Koninklijke Philips N.V. | Methods for estimating heterogeneity of a tumour based on values for two or more genome mutation and/or gene expression related parameter, as well as corresponding devices |
EP3974540A1 (en) | 2020-09-25 | 2022-03-30 | Koninklijke Philips N.V. | Method for predicting immunotherapy resistance |
EP4015651A1 (en) | 2020-12-17 | 2022-06-22 | Koninklijke Philips N.V. | Treatment prediction and effectiveness of anti-tnf alpha treatment in ibd patients |
CN112466403B (zh) * | 2020-12-31 | 2022-06-14 | 广州基迪奥生物科技有限公司 | 一种细胞通讯分析方法及系统 |
EP4039825A1 (en) | 2021-02-09 | 2022-08-10 | Koninklijke Philips N.V. | Comparison and standardization of cell and tissue culture |
WO2022189530A1 (en) | 2021-03-11 | 2022-09-15 | Koninklijke Philips N.V. | Prognostic pathways for high risk sepsis patients |
CN114015709B (zh) * | 2021-11-04 | 2023-04-25 | 塔里木大学 | 绵羊ctsd基因在调控初情期启动中的应用 |
WO2023084039A1 (en) | 2021-11-15 | 2023-05-19 | Innosign B.V. | Assessment of gr cellular signaling pathway activity using mathematical modelling of target gene expression |
CN114703227B (zh) * | 2022-01-27 | 2023-11-10 | 中国科学院生态环境研究中心 | 基于MCF-7细胞系构建的RARα效应物体外筛选方法 |
US20230281310A1 (en) * | 2022-03-01 | 2023-09-07 | Meta Plataforms, Inc. | Systems and methods of uncertainty-aware self-supervised-learning for malware and threat detection |
CN114959057B (zh) * | 2022-05-25 | 2024-06-21 | 山西农业大学 | 与猪骨骼肌卫星细胞增殖相关的circRNA及其应用 |
WO2024033063A1 (en) | 2022-08-12 | 2024-02-15 | Innosign B.V. | Prediction and monitoring of immunotherapy in cancer |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003260973A1 (en) | 2002-09-05 | 2004-03-29 | Toolgen, Inc. | Bioinformatics analysis of cellular effects of artificial transcription factors |
WO2005029067A2 (en) * | 2003-09-24 | 2005-03-31 | Oncotherapy Science, Inc. | Method of diagnosing breast cancer |
AU2004296023A1 (en) | 2003-11-26 | 2005-06-16 | Genstruct, Inc. | System, method and apparatus for causal implication analysis in biological networks |
EP1842147A2 (en) * | 2005-01-24 | 2007-10-10 | The Board of Trustees of The Leland Stanford Junior University | Method for modeling cell signaling systems by means of bayesian networks |
CA2651929A1 (en) | 2006-05-17 | 2007-11-29 | Timothy S. Gardner | Method to determine transcriptional regulation pathways in organisms |
US20080317745A1 (en) * | 2006-09-15 | 2008-12-25 | Boruchov Adam M | Methods of diagnosing, treating, or preventing plasma cell disorders |
US7629125B2 (en) * | 2006-11-16 | 2009-12-08 | General Electric Company | Sequential analysis of biological samples |
CA2673133C (en) * | 2006-12-22 | 2016-08-30 | Clf Medical Technology Acceleration Program, Inc. | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
EP2217223A2 (en) * | 2007-11-05 | 2010-08-18 | Novartis AG | Methods and compositions for measuring wnt activation and for treating wnt-related cancers |
US8483970B2 (en) * | 2008-09-29 | 2013-07-09 | The Trustees Of Columbia University In The City Of New York | Method for identifying aQTL regions whose genotype modulates transcription factor activity |
US10192641B2 (en) | 2010-04-29 | 2019-01-29 | The Regents Of The University Of California | Method of generating a dynamic pathway map |
CA2796272C (en) | 2010-04-29 | 2019-10-01 | The Regents Of The University Of California | Pathway recognition algorithm using data integration on genomic models (paradigm) |
EP2663323B1 (en) * | 2011-01-14 | 2017-08-16 | The General Hospital Corporation | Methods targeting mir-128 for regulating cholesterol/lipid metabolism |
RU2633293C2 (ru) | 2011-04-26 | 2017-10-11 | Конинклейке Филипс Н.В. | Диагностическая визуализация головного мозга |
EP2549399A1 (en) | 2011-07-19 | 2013-01-23 | Koninklijke Philips Electronics N.V. | Assessment of Wnt pathway activity using probabilistic modeling of target gene expression |
-
2013
- 2013-12-18 AU AU2013368945A patent/AU2013368945B2/en active Active
- 2013-12-18 CN CN202010822828.0A patent/CN111961726A/zh active Pending
- 2013-12-18 ES ES13831865T patent/ES2878196T3/es active Active
- 2013-12-18 MX MX2015008177A patent/MX2015008177A/es active IP Right Grant
- 2013-12-18 WO PCT/IB2013/061066 patent/WO2014102668A2/en active Application Filing
- 2013-12-18 DK DK13831865.4T patent/DK2938745T3/da active
- 2013-12-18 CA CA2896414A patent/CA2896414C/en active Active
- 2013-12-18 EP EP13831865.4A patent/EP2938745B1/en active Active
- 2013-12-18 BR BR112015015131A patent/BR112015015131A2/pt not_active Application Discontinuation
- 2013-12-18 KR KR1020157020316A patent/KR102279844B1/ko active IP Right Grant
- 2013-12-18 JP JP2015550178A patent/JP6449779B2/ja not_active Expired - Fee Related
- 2013-12-18 CN CN201380073861.6A patent/CN105074005A/zh active Pending
- 2013-12-18 US US14/652,805 patent/US11306360B2/en active Active
- 2013-12-18 RU RU2015131009A patent/RU2721130C2/ru active
-
2018
- 2018-12-06 JP JP2018228883A patent/JP6721665B2/ja active Active
-
2020
- 2020-04-22 AU AU2020202706A patent/AU2020202706B2/en active Active
-
2022
- 2022-04-06 US US17/714,335 patent/US20230030858A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2016509472A (ja) | 2016-03-31 |
JP2019076096A (ja) | 2019-05-23 |
US11306360B2 (en) | 2022-04-19 |
WO2014102668A2 (en) | 2014-07-03 |
CN111961726A (zh) | 2020-11-20 |
EP2938745B1 (en) | 2020-10-07 |
US20230030858A1 (en) | 2023-02-02 |
CA2896414A1 (en) | 2014-07-03 |
AU2020202706B2 (en) | 2022-06-16 |
CN105074005A (zh) | 2015-11-18 |
KR102279844B1 (ko) | 2021-07-21 |
AU2020202706A1 (en) | 2020-05-14 |
AU2013368945B2 (en) | 2020-01-23 |
KR20150100896A (ko) | 2015-09-02 |
CA2896414C (en) | 2023-06-20 |
DK2938745T3 (da) | 2020-11-30 |
ES2878196T3 (es) | 2021-11-18 |
WO2014102668A3 (en) | 2014-08-21 |
AU2013368945A1 (en) | 2015-08-13 |
EP2938745A2 (en) | 2015-11-04 |
JP6449779B2 (ja) | 2019-01-09 |
MX2015008177A (es) | 2015-09-16 |
JP6721665B2 (ja) | 2020-07-15 |
US20150347672A1 (en) | 2015-12-03 |
RU2721130C2 (ru) | 2020-05-18 |
RU2015131009A (ru) | 2017-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015015131A2 (pt) | método, aparelho, mídia de armazenamento não transitório, programa de computador, e produto | |
BR112016003868A2 (pt) | método, aparelho, mídia de armazenamento não transitório, e, programa de computador | |
BR112014000965B8 (pt) | Método, aparelho e meio de armazenamento não transitório | |
Neri et al. | Molecular mechanisms contributing to mesenchymal stromal cell aging | |
BR112017026709A2 (pt) | tratamento e diagnóstico de câncer | |
BR112018002848A2 (pt) | método, aparelho, mídia de armazenamento não transitório, programa de computador, kit para medir níveis de expressão de seis ou mais genes-alvo da via de sinalização celular | |
BR112017007965A2 (pt) | método implantado por computador para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; aparelho para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; meio de armazenamento não transitório; programa de computador; kits para medir níveis de expressão de três ou mais genes-alvo da via de sinalização celular de tgf-b em uma amostra de um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; e uso do kit | |
BR112017004349A2 (pt) | terapia com gene de globina para o tratamento de hemoglobinopatias | |
BR112013010015A2 (pt) | aparelho e método para detecção não invasiva de doenças que afetam as propriedades estruturais em tecidos biológicos | |
BR112015024605A2 (pt) | sistemas e métodos para a produção visada de proteína terapêutica dentro de célula alvo | |
BR112015026601A2 (pt) | método para um ensaio de triagem de fármaco à base de células e o uso do mesmo | |
BR112016024143A2 (pt) | tratamento de câncer | |
WO2014124339A3 (en) | Use of translational profiling to identify target molecules for therapeutic treatment | |
EP4252742A3 (en) | Fluticasone furoate in the treatment of copd | |
BR112018003238A2 (pt) | seleção de pacientes para terapia de combinação | |
BR112017011012A2 (pt) | método baseado em célula para determinar a potência de defibrotide | |
BR112016002709A2 (pt) | queratinas como biomarcadores para câncer cervical e sobrevivência | |
Nakadate et al. | Pathological changes in hepatocytes of mice with obesity-induced type 2 diabetes by monosodium glutamate | |
CY1112352T1 (el) | Μεθοδος προβλεψης αποκρισιμοτητας σε φαρμακευτικη θεραπεια για παχυσαρκια | |
JP2014208601A5 (pt) | ||
BR112014015654A8 (pt) | método; sistema; e meio de armazenamento não transitório informático que armazena um conjunto de instruções executáveis por um processador | |
Kendrick | Detection of chronic wound infection using impedance spectroscopy | |
Wang et al. | Clinical Significance of IL-22 Expression and Percentage of IL-22-producing Th22 Cells in Primary Sj? gren′ s Syndrome | |
宋涛 et al. | Correlation analysis between the expression of P21WAF1/CIP1, P16 proteins and human glioma | |
Qiuhong et al. | Investigation and analysis on ABO and Rh blood groups distribution among Zhuang polulation in Nanning area |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |